

# William Tillett

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1211953/william-tillett-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76  
papers

1,459  
citations

22  
h-index

36  
g-index

111  
ext. papers

1,886  
ext. citations

4.4  
avg, IF

4.43  
L-index

#	Paper	IF	Citations
76	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 673-680	2.4	138
75	Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1358-61	2.4	109
74	The CLASSification for Psoriatic ARthritis (CASPAR) criteria--a retrospective feasibility, sensitivity, and specificity study. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 154-6	4.1	96
73	Work disability in psoriatic arthritis: a systematic review. <i>Rheumatology</i> , <b>2012</b> , 51, 275-83	3.9	74
72	The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. <i>Rheumatology</i> , <b>2013</b> , 52, 1754-7	3.9	72
71	Input-and layer-dependent synaptic plasticity in the rat perirhinal cortex in vitro. <i>Neuroscience</i> , <b>1999</b> , 92, 459-72	3.9	70
70	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1522-1528	4.1	66
69	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 345-355	9.5	51
68	Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	47
67	Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. <i>Rheumatology</i> , <b>2015</b> , 54, 157-62	3.9	46
66	Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. <i>Rheumatology</i> , <b>2017</b> , 56, 2109-2113	3.9	38
65	Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 277-280	2.4	32
64	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 47, 654-665	5.3	32
63	Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. <i>Rheumatology</i> , <b>2013</b> , 52, 261-6	3.9	30
62	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 697-700	4.1	29
61	Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2198-203	4.1	29
60	Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 714-720	4	29

59	Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study. <i>Patient</i> , <b>2017</b> , 10, 455-462	3.7	27
58	Patient involvement in outcome measures for psoriatic arthritis. <i>Current Rheumatology Reports</i> , <b>2014</b> , 16, 418	4.9	27
57	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 990-995	4.1	26
56	Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 343-347	2.4	24
55	Perspectives of Patients With Rheumatic Diseases in the Early Phase of COVID-19. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1189-1195	4.7	23
54	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 965-9	4.1	22
53	Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1198-1205	4.7	22
52	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 996-1005	4.1	21
51	Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1169-76	4.1	19
50	Feasibility, reliability, and sensitivity to change of four radiographic scoring methods in patients with psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 311-7	4.7	19
49	Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. <i>Rheumatology</i> , <b>2017</b> , 56, 603-612	3.9	15
48	Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. <i>Rheumatology</i> , <b>2019</b> , 58, 144-148	3.9	15
47	Classification and Outcome Measures for Psoriatic Arthritis. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 246	4.9	15
46	Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1206-11	4.1	12
45	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, e23	2.4	10
44	Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 903-919	4.4	10
43	A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1445-1452	4.1	9
42	Treatment algorithms for early psoriatic arthritis: do they depend on disease phenotype?. <i>Current Rheumatology Reports</i> , <b>2012</b> , 14, 334-42	4.9	9

41	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , <b>2019</b> , 95, 33-37	4.1	9
40	Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis. <i>Rheumatology</i> , <b>2019</b> , 58, 269-273	3.9	9
39	Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). <i>Rheumatology</i> , <b>2020</b> , 59, 1495-1504	3.9	9
38	A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire. <i>Rheumatology and Therapy</i> , <b>2019</b> , 6, 379-391	4.4	8
37	Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1021-1026	4.1	8
36	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2018</b> , 94, 17-25	4.1	8
35	Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 617-637	4.4	8
34	Psoriatic Nail Dystrophy Is Associated with Erosive Disease in the Distal Interphalangeal Joints in Psoriatic Arthritis: A Retrospective Cohort Study. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1097-1102	4.1	7
33	Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 701-707	4.1	7
32	Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1048-1051	4.1	6
31	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 59	5.1	6
30	Joint count reliability in psoriatic arthritis observational trials--an unreported problem. <i>Rheumatology</i> , <b>2012</b> , 51, 1333-4	3.9	4
29	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1158-1181	5.3	4
28	Diagnosis, classification, and assessment in psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2021</b> , 35, 101669	5.3	4
27	Comment on: Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement. <i>Rheumatology</i> , <b>2018</b> , 57, 401-402	3.9	3
26	Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 970-3	4.1	3
25	Novel Composite Radiographic Score for Longitudinal Observational Studies of Psoriatic Arthritis: A Proof-of-concept Study. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 367-70	4.1	3
24	GRAPPA Trainees Symposium 2014: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1016-1020	4.1	3

23	The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database. <i>Journal of Rheumatology</i> , <b>2018</b> , 94, 26-29	4.1	3
22	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2020</b> , 5, 12-22	1.1	3
21	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. <i>Journal of Rheumatology</i> , <b>2021</b> ,	4.1	3
20	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 58-66	4.1	3
19	Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase III Studies. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1223-1240	4.4	2
18	Diagnosis and initial management in psoriatic arthritis: a qualitative study with patients. <i>Rheumatology Advances in Practice</i> , <b>2019</b> , 3, rkz022	1.1	1
17	The Natural History of Psoriatic Arthritis <b>2016</b> , 39-42		1
16	Evaluation of a patient self-stratification methodology to identify those in need of shielding during COVID-19. <i>Clinical Medicine</i> , <b>2020</b> , 20, e212-e214	1.9	1
15	Using Bayesian Networks to identify musculoskeletal symptoms influencing the risk of developing Psoriatic Arthritis in people with psoriasis. <i>Rheumatology</i> , <b>2021</b> ,	3.9	1
14	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1547-1551	4.1	1
13	Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1268-1271	4.1	1
12	Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design. <i>Trials</i> , <b>2021</b> , 22, 185	2.8	1
11	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 1117-1124	5.3	1
10	Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 1227-1230	2.2	1
9	Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. <i>Lancet Rheumatology, The</i> , <b>2022</b> , 4, e262-e273	14.2	1
8	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. <i>Rheumatology</i> , <b>2021</b> , 60, 1588-1592	3.9	0
7	Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry.. <i>Rheumatology and Therapy</i> , <b>2022</b> , 9, 735	4.4	0
6	Patient information leaflets: a study of patient and physician satisfaction. <i>Journal of Clinical Rheumatology</i> , <b>2014</b> , 20, 453	1.1	

5	Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211057668	3.8
4	Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H. <i>Rheumatology and Therapy</i> , <b>2021</b> , 1	4.4
3	Preliminary Validation of the Severity of Nail Psoriasis Score (SNAPS) for the Assessment of Nail Psoriasis in Patients With Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2021</b> , 6, 128-135	1.1
2	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 367-386	5.3
1	Risk of Osteoarthritis in an Incident Cohort of People With Psoriatic Arthritis: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 841-846	4.1